Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 177Lu-PSMA-I&T
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Partnership
Curium Partners with PeptiDream for Prostate Cancer Theranostics in Japan
Details : Under the terms of the partnership, Curium and PDRadiopharma will jointly collaborate on clinical development activities of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan.
Brand Name : 177Lu-PSMA-I&T
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 01, 2024
Lead Product(s) : 177Lu-PSMA-I&T
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?